Berlin: Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on norucholic acid (NCA) in primary sclerosing cholangitis (PSC).
According to BERNAMA News Agency, the study results demonstrate the superiority of norucholic acid over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at the 2025 EASL Congress in Amsterdam.